JP2025509965A5 - - Google Patents
Info
- Publication number
- JP2025509965A5 JP2025509965A5 JP2024556140A JP2024556140A JP2025509965A5 JP 2025509965 A5 JP2025509965 A5 JP 2025509965A5 JP 2024556140 A JP2024556140 A JP 2024556140A JP 2024556140 A JP2024556140 A JP 2024556140A JP 2025509965 A5 JP2025509965 A5 JP 2025509965A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- compound
- alkyl
- cancer
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263323339P | 2022-03-24 | 2022-03-24 | |
| US63/323,339 | 2022-03-24 | ||
| PCT/US2023/016132 WO2023183520A1 (en) | 2022-03-24 | 2023-03-23 | Compositions and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509965A JP2025509965A (ja) | 2025-04-11 |
| JP2025509965A5 true JP2025509965A5 (https=) | 2026-03-31 |
Family
ID=88102078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556140A Pending JP2025509965A (ja) | 2022-03-24 | 2023-03-23 | がんを治療するための組成物及び方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250206728A1 (https=) |
| EP (1) | EP4499625A4 (https=) |
| JP (1) | JP2025509965A (https=) |
| KR (1) | KR20250005157A (https=) |
| CN (2) | CN119522217A (https=) |
| AU (1) | AU2023241042A1 (https=) |
| CA (1) | CA3246244A1 (https=) |
| IL (1) | IL315800A (https=) |
| TW (1) | TW202400575A (https=) |
| WO (1) | WO2023183520A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
| TW202530204A (zh) * | 2023-09-27 | 2025-08-01 | 美商Ａ２Ａ製藥公司 | 用於治療與轉化酸性捲曲螺旋蛋白相關的癌症的方法 |
| WO2026026956A1 (zh) * | 2024-08-02 | 2026-02-05 | 北京康辰药业股份有限公司 | Tacc抑制剂化合物、药物组合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7115617B2 (en) | 2001-08-22 | 2006-10-03 | Amgen Inc. | Amino-substituted pyrimidinyl derivatives and methods of use |
| EP1794135A1 (en) * | 2004-09-27 | 2007-06-13 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| US20080207572A1 (en) | 2005-07-14 | 2008-08-28 | Ab Science | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma |
| EP2043651A2 (en) | 2006-07-05 | 2009-04-08 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
| US20130023534A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Pyrazolyl-pyrimidines as kinase inhibitors |
| JP5947818B2 (ja) * | 2011-03-02 | 2016-07-06 | リード ディスカバリー センター ゲーエムベーハー | 薬学的活性化二置換ピリジン誘導体 |
| PE20142098A1 (es) * | 2012-01-06 | 2015-01-08 | Agios Pharmaceuticals Inc | Compuestos terapeuticamente activos y sus metodos de uso |
| JP6008305B2 (ja) | 2012-05-02 | 2016-10-19 | 公益財団法人がん研究会 | Ｔａｃｃ３を標的とする小化合物 |
| WO2015082583A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| US9796701B2 (en) | 2013-12-31 | 2017-10-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| JP6682221B2 (ja) | 2014-09-24 | 2020-04-15 | 公益財団法人がん研究会 | Ｔａｃｃ３阻害剤のスクリーニング方法 |
| EP3070084A1 (en) | 2015-03-18 | 2016-09-21 | Rottapharm Biotech S.r.l. | New fyn kinase inhibitors |
| WO2016173557A1 (zh) | 2015-04-30 | 2016-11-03 | 中国科学院上海药物研究所 | 一类具有激酶抑制活性的化合物、制备方法和用途 |
| MX2017015574A (es) | 2015-06-02 | 2018-08-09 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| TWI620748B (zh) | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
| ES2805976T3 (es) | 2016-06-30 | 2021-02-16 | Janssen Pharmaceutica Nv | Derivados heteroaromáticos en calidad de inhibidores de NIK |
| WO2018045957A1 (zh) | 2016-09-07 | 2018-03-15 | 江苏豪森药业集团有限公司 | 一种cdk4/6抑制剂及其制备方法和应用 |
| WO2018124001A1 (ja) | 2016-12-27 | 2018-07-05 | 国立研究開発法人理化学研究所 | Ｂｍｐシグナル阻害化合物 |
| CN107089968B (zh) | 2017-04-12 | 2019-06-18 | 南方医科大学 | 1-(2-氨基吡啶-4-基)-3-哌啶甲酰胺衍生物及其合成方法和应用 |
| TWI667236B (zh) | 2017-06-13 | 2019-08-01 | 財團法人國家衛生研究院 | 作為蛋白激酶抑制劑的胺基噻唑化合物 |
| MX2020004536A (es) | 2017-11-23 | 2020-08-03 | Biomed X Gmbh | Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka). |
| JP2021514359A (ja) | 2018-02-15 | 2021-06-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | キナーゼ阻害剤としての複素環式化合物 |
| WO2019177374A1 (ko) | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 |
| CN112469414A (zh) | 2018-05-25 | 2021-03-09 | 昂科库博疗法有限责任公司 | 作为新型候选抗癌药物的高效力tacc3抑制剂 |
| CN114502536A (zh) | 2019-08-14 | 2022-05-13 | 诺维逊生物股份有限公司 | 作为激酶抑制剂的杂环化合物 |
| CN115279754A (zh) * | 2019-11-14 | 2022-11-01 | A2A制药有限公司 | 靶向tacc3的异恶唑衍生物作为抗癌剂 |
| KR20240005751A (ko) | 2021-04-12 | 2024-01-12 | 에이2에이 파마수티칼스, 잉크. | 암 치료를 위한 조성물 및 방법 |
| EP4198097B1 (en) | 2021-12-15 | 2024-05-29 | Ricoh Company, Ltd. | Image forming method and active energy ray-curable composition set |
| EP4499625A4 (en) | 2022-03-24 | 2026-03-18 | A2A Pharmaceuticals Inc | CANCER COMPOSITIONS AND TREATMENT METHODS |
-
2023
- 2023-03-23 EP EP23775685.3A patent/EP4499625A4/en active Pending
- 2023-03-23 CA CA3246244A patent/CA3246244A1/en active Pending
- 2023-03-23 CN CN202380041923.9A patent/CN119522217A/zh active Pending
- 2023-03-23 AU AU2023241042A patent/AU2023241042A1/en active Pending
- 2023-03-23 WO PCT/US2023/016132 patent/WO2023183520A1/en not_active Ceased
- 2023-03-23 JP JP2024556140A patent/JP2025509965A/ja active Pending
- 2023-03-23 IL IL315800A patent/IL315800A/en unknown
- 2023-03-23 TW TW112110936A patent/TW202400575A/zh unknown
- 2023-03-23 US US18/849,309 patent/US20250206728A1/en active Pending
- 2023-03-23 KR KR1020247035261A patent/KR20250005157A/ko active Pending
- 2023-03-23 CN CN202510379414.8A patent/CN120040441A/zh active Pending
- 2023-11-13 US US18/389,078 patent/US11986475B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025509965A5 (https=) | ||
| JP7033764B2 (ja) | Ｃｄｋ阻害剤としての置換型ヘテロシクリル誘導体 | |
| EP3189042B1 (en) | Tetrahydroisoquinoline derived prmt5-inhibitors | |
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| US10961256B2 (en) | PRMT5 inhibitors | |
| JP2019163277A (ja) | Ｅｇｆｒ変異型キナーゼ活性をモジュレートするための化合物および組成物 | |
| AU2019289888A1 (en) | Compounds | |
| EP2702055A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| JP2022526266A5 (https=) | ||
| EP3822263A1 (en) | Biaryl ether-type quinazoline derivative | |
| US10550096B2 (en) | Tetrahydroisoquinolines as PRMT5 inhibitors | |
| JPWO2019107386A1 (ja) | 抗腫瘍剤 | |
| US10787434B2 (en) | Benzopiperdine derivatives and their use in the treatment of cancer and hemoglobinopathies | |
| JP2022550353A (ja) | アザキノリン化合物およびその使用 | |
| CA3159211A1 (en) | Fluorinated quinoline, quinoxaline and benzo[b][1,4]oxazine derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases | |
| US10745380B2 (en) | Pyridine derivatives and their use in the treatment of cancer and hemoglobinopathies | |
| HK40045602B (en) | Urea compounds and compositions as smarca2/brm-atpase inhibitors | |
| HK40045602A (en) | Urea compounds and compositions as smarca2/brm-atpase inhibitors |